ArticleGastroenterology report2025
Long-term survival outcomes of proximal gastrectomy versus total gastrectomy in patients with T2-3 esophagogastric junction adenocarcinoma and upper third gastric adenocarcinoma: a propensity score-matching analysis.
Article in Gastroenterology report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to investigate long-term survival outcome in patients with locally advanced esophagogastric junction adenocarcinoma and upper third gastric adenocarcinoma (EGJ-UG adenocarcinoma) who underwent proximal gastrectomy (PG) or total gastrectomy (TG). Methods: We searched and analyzed the data from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with T2-3 EGJ-UG adenocarcinoma receiving TG or PG were included. We performed a propensity score 1:2 matching, and matched datasets were generated and compared.We obtained the patients' long-term survival benefits according to stratification of surgical approaches. Results: Of 1,291 patients identified from the SEER database, 901 (69.8%) patients received PG and 390 (30.2%) patients received TG. After matching, 584 patients in the PG group were matched by propensity score to 344 patients in the TG group. There were no differences in overall survival and cancer-specific survival in matched data between different surgical approaches. For patients with tumor size ≤4 cm, similar long-term survival was observed in patients receiving PG and TG. For patients with tumor size >4 cm, TG was associated with improved overall survival and cancer-specific survival compared with PG. Conclusion: This study has shown similar survival outcomes between PG and TG for patients with T2-3 EGJ-UG adenocarcinoma and with tumor size <4 cm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.